Perrigo Company plc Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$19.80 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-27 was -$19.80M, a 113.62% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-28 was -$7.80M, a 108.48% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$64.80M.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-27 was -$5.40M, a 108.44% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $167.20M.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$173.10M, a 559.15% decline from fiscal 2023.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $37.70M.
- Perrigo Company plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$62.50M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-27 | -$19.80M 10-Q · filed 2026-08-05 | -$27.60M 10-Q · filed 2026-08-05 | -$92.40M derived: sum of 3 quarters · filed 2026-08-05 | -$97.80M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-28 | -$7.80M 10-Q · filed 2026-08-05 | -$72.60M derived: sum of 2 quarters · filed 2026-08-05 | -$78.00M derived: sum of 3 quarters · filed 2026-08-05 | $67.40M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$64.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$70.20M derived: sum of 2 quarters · filed 2026-02-26 | $75.20M derived: sum of 3 quarters · filed 2026-08-05 | $167.20M 10-K · filed 2026-02-26 | |||
| 2025-09-27 | -$5.40M 10-Q · filed 2025-11-05 | $140.00M derived: sum of 2 quarters · filed 2026-08-05 | $232.00M 10-Q · filed 2025-11-05 | $59.80M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-28 | $145.40M 10-Q · filed 2026-08-05 | $237.40M 10-Q · filed 2026-08-05 | $65.20M derived: sum of 3 quarters · filed 2026-08-05 | $129.20M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-29 | $92.00M 10-Q · filed 2026-08-05 | -$80.20M derived: sum of 2 quarters · filed 2026-08-05 | -$16.20M derived: sum of 3 quarters · filed 2026-08-05 | -$32.70M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2024-12-31 | -$172.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$108.20M derived: sum of 2 quarters · filed 2026-02-26 | -$124.70M derived: sum of 3 quarters · filed 2026-02-26 | -$173.10M 10-K · filed 2026-02-26 | |||
| 2024-09-28 | $64.00M 10-Q · filed 2025-11-05 | $47.50M derived: sum of 2 quarters · filed 2025-11-05 | -$900.00K 10-Q · filed 2025-11-05 | $87.90M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-29 | -$16.50M 10-Q · filed 2025-11-05 | -$64.90M 10-Q · filed 2025-08-06 | $23.90M derived: sum of 3 quarters · filed 2026-02-26 | -$74.10M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-30 | -$48.40M 10-Q · filed 2025-11-05 | $40.40M derived: sum of 2 quarters · filed 2026-02-26 | -$57.60M derived: sum of 3 quarters · filed 2026-02-26 | -$31.40M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $88.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$9.20M derived: sum of 2 quarters · filed 2026-02-26 | $17.00M derived: sum of 3 quarters · filed 2026-02-26 | $37.70M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$98.00M 10-Q · filed 2024-11-06 | -$71.80M derived: sum of 2 quarters · filed 2024-11-06 | -$51.10M 10-Q · filed 2024-11-06 | $239.30M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-07-01 | $26.20M 10-Q · filed 2024-11-06 | $46.90M 10-Q · filed 2024-08-02 | $337.30M derived: sum of 3 quarters · filed 2025-02-28 | $167.00M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-04-01 | $20.70M 10-Q · filed 2024-11-06 | $311.10M derived: sum of 2 quarters · filed 2025-02-28 | $140.80M derived: sum of 3 quarters · filed 2025-02-28 | -$21.00M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2022-12-31 | $290.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $120.10M derived: sum of 2 quarters · filed 2025-02-28 | -$41.70M derived: sum of 3 quarters · filed 2025-02-28 | -$62.50M 10-K · filed 2025-02-28 | |||
| 2022-10-01 | -$170.30M 10-Q · filed 2023-11-07 | -$332.10M derived: sum of 2 quarters · filed 2023-11-07 | -$352.90M 10-Q · filed 2023-11-07 | -$352.60M 10-Q · filed 2022-11-08 | -$371.30M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-07-02 | -$161.80M 10-Q · filed 2023-11-07 | -$182.30M 10-Q · filed 2023-08-08 | -$201.00M derived: sum of 3 quarters · filed 2024-02-27 | -$453.90M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-04-02 | -$20.50M 10-Q · filed 2023-11-07 | -$39.20M derived: sum of 2 quarters · filed 2024-02-27 | -$292.10M derived: sum of 3 quarters · filed 2024-02-27 | -$261.70M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | -$18.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$271.60M derived: sum of 2 quarters · filed 2024-02-27 | -$241.20M derived: sum of 3 quarters · filed 2024-02-27 | -$359.50M 10-K · filed 2024-02-27 | |||
| 2021-10-02 | -$252.90M 10-Q · filed 2022-11-08 | -$222.50M derived: sum of 2 quarters · filed 2022-11-08 | -$340.80M 10-Q · filed 2022-11-08 | -$149.50M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-07-03 | $30.40M 10-Q · filed 2022-11-08 | -$87.90M 10-Q · filed 2022-08-09 | $103.40M derived: sum of 3 quarters · filed 2023-02-28 | $186.40M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-04-03 | -$118.30M 10-Q · filed 2022-11-08 | $73.00M derived: sum of 2 quarters · filed 2023-02-28 | $156.00M derived: sum of 3 quarters · filed 2023-02-28 | $240.80M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $191.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $274.30M derived: sum of 2 quarters · filed 2023-02-28 | $359.10M derived: sum of 3 quarters · filed 2023-02-28 | $255.60M 10-K · filed 2023-02-28 | |||
| 2020-09-26 | $83.00M 10-Q · filed 2021-11-12 | $167.80M derived: sum of 2 quarters · filed 2021-11-12 | $64.30M 10-Q · filed 2021-11-12 | $147.10M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-27 | $84.80M 10-Q · filed 2021-11-12 | -$18.70M 10-Q · filed 2021-08-11 | $64.10M derived: sum of 3 quarters · filed 2022-03-01 | $21.20M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-28 | -$103.50M 10-Q · filed 2021-11-12 | -$20.70M derived: sum of 2 quarters · filed 2022-03-01 | -$63.60M derived: sum of 3 quarters · filed 2022-03-01 | -$33.10M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $82.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $39.90M derived: sum of 2 quarters · filed 2022-03-01 | $70.40M derived: sum of 3 quarters · filed 2022-03-01 | $54.80M 10-K · filed 2022-03-01 | |||
| 2019-09-28 | -$42.90M 10-Q · filed 2020-11-05 | -$12.40M derived: sum of 2 quarters · filed 2020-11-05 | -$28.00M 10-Q · filed 2020-11-05 | -$86.60M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-29 | $30.50M 10-Q · filed 2020-11-05 | $14.90M 10-Q · filed 2020-08-05 | -$43.70M derived: sum of 3 quarters · filed 2021-03-01 | -$55.50M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-30 | -$15.60M 10-Q · filed 2020-11-05 | -$74.20M derived: sum of 2 quarters · filed 2021-03-01 | -$86.00M derived: sum of 3 quarters · filed 2021-03-01 | -$255.30M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | -$58.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$70.40M derived: sum of 2 quarters · filed 2021-03-01 | -$239.70M derived: sum of 3 quarters · filed 2021-03-01 | -$167.50M 10-K · filed 2021-03-01 | |||
| 2018-09-29 | -$11.80M 10-Q · filed 2019-11-06 | -$181.10M derived: sum of 2 quarters · filed 2019-11-06 | -$108.90M 10-Q · filed 2019-11-06 | -$47.00M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | -$169.30M 10-Q · filed 2019-11-06 | -$97.10M 10-Q · filed 2019-08-08 | -$35.20M derived: sum of 3 quarters · filed 2020-02-27 | $25.50M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $72.20M 10-Q · filed 2019-11-06 | $134.10M derived: sum of 2 quarters · filed 2020-02-27 | $194.80M derived: sum of 3 quarters · filed 2020-02-27 | $351.60M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $61.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $122.60M derived: sum of 2 quarters · filed 2020-02-27 | $279.40M derived: sum of 3 quarters · filed 2020-02-27 | $334.90M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $60.70M 10-Q · filed 2018-11-08 | $217.50M derived: sum of 2 quarters · filed 2018-11-08 | $273.00M 10-Q · filed 2018-11-08 | ||||
| 2017-07-01 | $156.80M 10-Q · filed 2018-08-09 | $212.30M 10-Q · filed 2018-08-09 | |||||
| 2016-12-31 | -$66.50M 10-K · filed 2019-02-27 | ||||||
| 2015-12-31 | -$118.80M 10-K · filed 2018-03-01 | -$117.90M 10-KT · filed 2016-02-25 | |||||
| 2015-06-27 | -$36.10M 10-K · filed 2018-03-01 | -$37.20M 10-K · filed 2015-08-13 | |||||
| 2014-06-28 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $25.00M derived: sum of 2 quarters · filed 2017-05-22 | $35.30M derived: sum of 3 quarters · filed 2017-05-22 | $62.60M 10-K · filed 2017-05-22 | |||
| 2014-03-29 | $15.70M 10-Q · filed 2014-05-07 | $26.00M derived: sum of 2 quarters · filed 2014-05-07 | $53.30M 10-Q · filed 2014-05-07 | -$710.39K derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-12-28 | $10.30M 10-Q · filed 2014-02-06 | $37.60M 10-Q · filed 2014-02-06 | -$16.41M derived: sum of 3 quarters · filed 2016-02-25 | -$9.71M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-09-28 | -$16.51M 10-Q · filed 2013-11-04 | -$26.71M derived: sum of 2 quarters · filed 2016-02-25 | -$20.01M derived: sum of 3 quarters · filed 2016-02-25 | $14.19M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-06-29 | -$10.20M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | -$3.50M derived: sum of 2 quarters · filed 2016-02-25 | $30.70M derived: sum of 3 quarters · filed 2016-02-25 | $37.60M 10-KT · filed 2016-02-25 | |||
| 2013-03-30 | $6.70M 10-Q · filed 2014-05-07 | $40.90M derived: sum of 2 quarters · filed 2014-05-07 | $47.80M 10-Q · filed 2014-05-07 | ||||
| 2012-12-29 | $34.20M 10-Q · filed 2014-02-06 | $41.20M 10-Q · filed 2014-02-06 | |||||
| 2012-06-30 | -$87.60M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |